Yohan Suryo Rahmanto
6PUBLICATIONS
18CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Aug 30, 2020
Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.Yao-An Shen, Jiaxin Hong, Ryoichi Asaka
|Jun 03, 2020
Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.Yohan Suryo Rahmanto, Wenjing Shen, Xu Shi
|Nov 27, 2019
Therapeutic Inducers of Apoptosis in Ovarian Cancer.Mudra Binju, Monica Angelica Amaya-Padilla, Graeme Wan
|Jun 15, 2019
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.Youngran Park, M Herman Chui, Yohan Suryo Rahmanto
|Mar 19, 2019
TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target.Lin-Yu Chen, Rui-Lan Huang, Michael Wy Chan
|Apr 13, 2018
Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway.Yu Yu, Yohan Suryo Rahmanto, Meng-Horng Lee
Pageof 1
Frequent Collaborators
2 joint publications
Stephanie Gaillard
2 joint publications
Yu Yu
2 joint publications
Shiho Asaka
1 joint publications
Lin-Yu Chen
1 joint publications
Rui-Lan Huang
1 joint publications
Po-Hsuan Su
1 joint publications
Ie-Ming Shih
1 joint publications
Youngran Park
1 joint publications
M Herman Chui
1 joint publications
Ayse Ayhan
